Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Videos

In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.

Regulatory Roundup—August 2026

Articles

Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by phase 1 candidate MER511.

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

Four FDA approvals in the areas of HIV, diabetes, autoimmune disease, and COVID-19 vaccines came in a flurry in late August 2026. 

What to Know from the FDA’s End of August Activity

This week’s PharmTech.com content covered AI agent authority, hold-time and nitrosamine risk frameworks, biologics formulation, 3D bioprinting, and major oncology and dealmaking news.

PharmTech Weekly Roundup—August 28, 2026

Gary Watts, Head of Formulation Development at Abzena.

As the biologic pipeline diversifies across ADCs, bispecific antibodies, and fusion proteins, formulation science has become the critical discipline bridging molecular complexity and patient-ready therapy.

Strategies to Maximize Stability of Emerging Biologics

FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS(ON) inhibition for future drug development.

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

Centrix and University of Sussex launch a data analytics partnership to reduce development risk, rework and delays in early-stage pharma programs.

Can Predictive Modelling Fix Fragmented Pharma Development Data?

Anthony Tantuccio is a Fellow Scientist at Hovione and CT R&D Program Manager, with significant expertise in oral solid dosage forms, continuous tableting, PAT, and advanced control strategies. He previously held technical and innovation leadership roles at Bristol Myers Squibb and Merck & Co., where he contributed to the development and commercialization of continuous manufacturing platforms. At eHovione, Anthony helps shape the continuous tableting strategy by identifying and advancing projects that strengthen capability, reduce adoption barriers, and support business growth. His work connects technology development, client engagement, strategic partnerships, external scientific communication, and data-driven comparisons of continuous and batch operations to support broader adoption of continuous manufacturing.

Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations when supported by a material-property-driven development strategy.

Rethinking the Path from Spray-Dried Dispersions to Tablets: The Role of Continuous Direct Compression

Cheryl Barton is director of PharmaVision, 

European biotechs are advancing bioinks and high-resolution bioprinting for medical devices and regenerative tissues.

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe 

FDA priority review of Jemperli for biomarker-defined rectal cancer signals capacity, supply chain, and global filing shifts for manufacturers.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development